Roche Inks Up To $1.39B Deal For Goodwin-Advised Biotech
Swiss health care giant Roche AG has inked an agreement potentially worth up to $1.39 billion to buy Goodwin Procter-advised Promedior Inc., a privately backed biotech focused on developing treatments for...To view the full article, register now.
Already a subscriber? Click here to view full article